ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR136/058/SRR13648758/SRR13648758.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR136/061/SRR13648761/SRR13648761.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR136/059/SRR13648759/SRR13648759.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR136/062/SRR13648762/SRR13648762.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR136/057/SRR13648757/SRR13648757.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR136/060/SRR13648760/SRR13648760.fastq.gzprimary200OKGenomicsBeth Israel Deaconess Medical Centerhttps://www.ebi.ac.uk/ena/browser/view/PRJNA700438xref:EuropePMC:PMC8051863Blockade of 6-Phosphogluconate dehydrogenase generates CD8+ effector T cellswith enhanced anti-tumor functionENAfalseBlockade of 6-Phosphogluconate dehydrogenase generates CD8+ effector T cells with enhanced anti-tumor function2023-05-192022-03-05PRJNA700438